RABIA KAMAL: Open Payments
NPI 1457624371 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,634 in 64 payments from 12 companies in 2025. Trend: 2023 $1,925 · 2024 $525 · 2025 $1,634
Food & beverage: $1,624Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $305 |
| Otsuka America Pharmaceutical, Inc. | 9 | $290 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $220 |
| E.R. Squibb & Sons, L.L.C. | 3 | $176 |
| Axsome Therapeutics, Inc. | 9 | $170 |
| Supernus Pharmaceuticals, Inc. | 2 | $146 |
| Neurocrine BioSciences, Inc. | 5 | $130 |
| Vanda Pharmaceuticals Inc. | 4 | $73 |
| Janssen Pharmaceuticals, Inc | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
Products named: REXULTI, VRAYLAR, CAPLYTA, COBENFY, Auvelity, Qelbree, INGREZZA, FANAPT.
Industry payments across TX — which companies pay providers there.
